Lee Oh-Hyun, Roh Ji Woong, Kim Yongcheol, Im Eui, Cho Deok-Kyu
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, Korea.
Korean J Intern Med. 2025 Sep;40(5):759-766. doi: 10.3904/kjim.2024.399. Epub 2025 Mar 25.
BACKGROUND/AIMS: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity.
Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays.
Platelet reaction unit (PRU) values at 3 (157 ± 8 vs. 162 ± 6, p = 0.659), 6 (167 ± 9 vs. 158 ± 7, p = 0.370), and 12 months (155 ± 10 vs. 164 ± 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as ≥ 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503).
There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.
背景/目的：关于氯吡格雷与替戈拉赞之间相互作用的数据有限。我们比较了替戈拉赞和质子泵抑制剂（PPI）对血小板反应性的影响。
利用2020年3月至2023年1月的数据库数据，我们回顾性评估了262例在经皮冠状动脉介入治疗后接受替戈拉赞（n = 107）或PPI（n = 155）联合双联抗血小板治疗（包括阿司匹林和氯吡格雷）的患者。使用VerifyNow P2Y12分析评估血小板反应性。
两组在3个月（157±8 vs. 162±6，p = 0.659）、6个月（167±9 vs. 158±7，p = 0.370）和12个月（155±10 vs. 164±7，p = 0.448）时的血小板反应单位（PRU）值相似。治疗期间高血小板反应性（定义为PRU≥253）的发生率在两组间3个月（10.3% vs. 10.2%，p = 0.976）、6个月（7.0% vs. 8.2%，p = 1.000）和12个月（4.3% vs. 9.0%，p = 0.503）时也相似。
在接受PCI并接受氯吡格雷双联抗血小板治疗的患者中，替戈拉赞组和PPI组之间的血小板反应性无显著差异。
